Prasugrel-hydrochloride-PCR-4099-hydrochloride-DataSheet-生命科学试剂-MedChemExpress

1、Hotline: 400-820-3792Inhibitors Agonists Screening Librarieswww.MedChemEPrasugrel hydrochlorideCat. No.: HY-15284ACAS No.: 389574-19-0Synonyms: PCR 4099 (hydrochloride)分式: CHClFNOS分量: 409.9作靶点: P2Y Receptor作通路: GPCR/G Protein储存式: 4C, protect from light* In solvent : -80C, 6 months; -20C, 1 month (pr

2、otect fromlight)溶解性数据体外实验 DMSO : 41.67 mg/mL (101.66 mM; Need ultrasonic)Mass Solvent1 mg 5 mg 10 mg Concentration制备储备液1 mM 2.4396 mL 12.1981 mL 24.3962 mL5 mM 0.4879 mL 2.4396 mL 4.8792 mL10 mM 0.2440 mL 1.2198 mL 2.4396 mL请根据产品在不同溶剂中的溶解度，选择合适的溶剂配制储备液，并请注意储备液的保存式和期限。体内实验 请根据您的实验动物和给药式选择适当的溶解案，配制前请先

3、配制澄清的储备液，再依次添加助溶剂(为保证实验结果的可靠性，体内实验的作液，建议您现现配，当天使；澄清的储备液可以根据储存条件，适当保存；以下溶剂前的百分 指该溶剂在您配制终溶液中的体积占)：1. 请依序添加每种溶剂： 10% DMSO 40% PEG300 5% Tween-80 45% salineSolubility: 2.08 mg/mL (5.07 mM); Clear solution2. 请依序添加每种溶剂： 10% DMSO 90% (20% SBE-CD in saline)Solubility: 2.08 mg/mL (5.07 mM); Clear solution3.

4、请依序添加每种溶剂： 10% DMSO 90% corn oilSolubility: 2.08 mg/mL (5.07 mM); Clear solution1/2 Master of Small Molecules 您边的抑制剂师www.MedChemEBIOLOGICAL ACTIVITY物活性 Prasugrel hydrochloride (PCR 4099 hydrochloride)板抑制剂，IC50 为 1.8 M。IC50 & Target P2Y12 receptor.体外研究 Prasugrel (PCR 4099) is a novel platelet inhibit

5、or used for the reduction of thrombotic cardiovascular events(including stent thrombosis) in patients with acute coronary syndrome who are to be managed with PCI2.Prasugrel (PCR 4099) reduces the aggregation (clumping) of platelets by irreversibly binding to P2Y12receptors. In rat platelets, prasugr

6、el hydrochloride AM inhibited in vitro platelet aggregation induced by ADP(10 m) with an IC50 value of 1.8 m 2.REFERENCES1. Sugidachi A, et al. The greater in vivo antiplatelet effects of prasugrel as compared to clopidogrel reflect more efficient generation of itsactive metabolite with similar anti

7、platelet activity to that of clopidogrels active metabolite. J Thromb Haemost. 2007 Jul;5(7):1545-51. Epub2007 Apr 19.2. Baker WL, et al. Role of prasugrel, a novel P2Y(12) receptor antagonist, in the management of acute coronary syndromes. Am JCardiovasc Drugs. 2009;9(4):213-29.McePdfHeightCaution: Product has not been fully validated for medical applications.For research us